Marta Sanchez-Carbayo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Interests
Marta Sanchez-Carbayo has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Carlos Cordon-Cardo
Division of Molecular Pathology and
4 shared publicationsElizabeth Charytonowicz
Division of Molecular Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, NY 10021, USA
3 shared publications- Juan José Lozano
Bioinformatics Platform, Biomedical Research Networking Centre in Hepatic and Digestive Disease (CIBEREHD), 28029 Madrid, Spain
2 shared publications Agnes Viale
Genomics Core Laboratory, Memorial Sloan Kettering Cancer Center, 1275 York Ave., New York, NY 10021
1 shared publication- Alberto Muñoz
Centro de Investigacion Biomedica en Red Cancer (CIBERONC), Madrid, Spain
1 shared publication Angel R. Ortiz
From the Division of Molecular Pathology,* Memorial Sloan-Kettering Cancer Center, New York; the Departments of Molecular Genetics and Pathology and the Seaver Center for Bioinformatics,† Albert Einstein College of Medicine, Bronx; the Department of Physiology and Biophysics,‡ Mt. Sinai School of Medicine, New York; and the Center for Genomics and Human Genetics,§ North Shore-Long Island Jewish Research Institute, Manhasset, New York
1 shared publication
Latest Publications
- 1 July 2004
- Published by Elsevier in Clinical Biochemistry
- Vol. 37 (7) , 562-571
Recent advances in bladder cancer diagnostics
- 1 July 2004
- Published by Elsevier in Clinical Biochemistry
- Vol. 37 (7) , 562-571
Recent advances in bladder cancer diagnostics
- Open Access
- 12 December 2003
- Published by Springer Nature in British Journal of Cancer
- Vol. 89 (12) , 2172-2177
Applications of array technology: identification of molecular targets in bladder cancer
High-throughput microarrays are being used in expression profiling analyses with the objecties of gene and pathway discovery, functional characterization of genes, and tumor subclassification. This review summarizes bladder cancer studies dealing with both in vitro models and clinical specimens, using distinct microarray platforms for target discovery.
- 12 December 2003
- Published by Springer Nature in British Journal of Cancer
- Vol. 89 (12) , 2172-2177
Open AccessApplications of array technology: identification of molecular targets in bladder cancer
High-throughput microarrays are being used in expression profiling analyses with the objecties of gene and pathway discovery, functional characterization of genes, and tumor subclassification. This review summarizes bladder cancer studies dealing with both in vitro models and clinical specimens, using distinct microarray platforms for target discovery.
- 1 December 2003
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 49 (12) , 2096-2100
Comparison of Gene Expression Profiles in Laser-Microdissected, Nonembedded, and OCT-Embedded Tumor Samples by Oligonucleotide Microarray Analysis
- 1 December 2003
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 49 (12) , 2096-2100
Comparison of Gene Expression Profiles in Laser-Microdissected, Nonembedded, and OCT-Embedded Tumor Samples by Oligonucleotide Microarray Analysis
- 15 November 2003
- Vol. 63 (22) , 7799-806
Genetic signatures of differentiation induced by 1alpha,25-dihydroxyvitamin D3 in human colon cancer cells.
Epidemiological and preclinical data indicate that vitamin D and its most active metabolite 1alpha,25-dihydroxyvitamin D(3) [1alpha,25(OH)(2)D(3)] have anticancer activity. Accordingly, clinical trials are under way using several nonhypercalcemic 1alpha,25(OH)(2)D(3) analogues against various neoplasms including colon cancer. 1alpha,25(OH)(2)D(3) induces proliferation arrest and epithelial differentiation of human SW480-ADH colon cancer cells. We examined the gene expression profiles associated with 1alpha,25(OH)(2)D(3) exposure using oligonucleotide microarrays. 1alpha,25(OH)(2)D(3) changed the expression levels of numerous previously unreported genes, including many involved in transcription, cell adhesion, DNA synthesis, apoptosis, redox status, and intracellular signaling. Most genes were up-regulated, and only a small fraction were down-regulated. Fourteen of 17 candidate genes studied were validated as 1alpha,25(OH)(2)D(3) target genes by Northern and Western blotting or immunocytochemistry. They included c-JUN, JUNB, JUND, FREAC-1/FoxF1, ZNF-44/KOX7, plectin, filamin, keratin-13, G(0)S2, and the putative tumor suppressors NES-1 and protease M. There was little overlap between genes regulated after short (4 h) or long (48 h) exposure. Gene regulatory effects of 1alpha,25(OH)(2)D(3) in SW480-ADH cells differed from those in LS-174T cells, which lack E-cadherin and do not differentiate in response to 1alpha,25(OH)(2)D(3). Data from this study reveal that 1alpha,25(OH)(2)D(3) causes a profound change in gene expression profiles and provide a mechanistic basis to the ongoing clinical studies using nonhypercalcemic vitamin D(3) derivatives for colon cancer prevention and treatment.
- 15 November 2003
- Vol. 63 (22) , 7799-806
Genetic signatures of differentiation induced by 1alpha,25-dihydroxyvitamin D3 in human colon cancer cells.
Epidemiological and preclinical data indicate that vitamin D and its most active metabolite 1alpha,25-dihydroxyvitamin D(3) [1alpha,25(OH)(2)D(3)] have anticancer activity. Accordingly, clinical trials are under way using several nonhypercalcemic 1alpha,25(OH)(2)D(3) analogues against various neoplasms including colon cancer. 1alpha,25(OH)(2)D(3) induces proliferation arrest and epithelial differentiation of human SW480-ADH colon cancer cells. We examined the gene expression profiles associated with 1alpha,25(OH)(2)D(3) exposure using oligonucleotide microarrays. 1alpha,25(OH)(2)D(3) changed the expression levels of numerous previously unreported genes, including many involved in transcription, cell adhesion, DNA synthesis, apoptosis, redox status, and intracellular signaling. Most genes were up-regulated, and only a small fraction were down-regulated. Fourteen of 17 candidate genes studied were validated as 1alpha,25(OH)(2)D(3) target genes by Northern and Western blotting or immunocytochemistry. They included c-JUN, JUNB, JUND, FREAC-1/FoxF1, ZNF-44/KOX7, plectin, filamin, keratin-13, G(0)S2, and the putative tumor suppressors NES-1 and protease M. There was little overlap between genes regulated after short (4 h) or long (48 h) exposure. Gene regulatory effects of 1alpha,25(OH)(2)D(3) in SW480-ADH cells differed from those in LS-174T cells, which lack E-cadherin and do not differentiate in response to 1alpha,25(OH)(2)D(3). Data from this study reveal that 1alpha,25(OH)(2)D(3) causes a profound change in gene expression profiles and provide a mechanistic basis to the ongoing clinical studies using nonhypercalcemic vitamin D(3) derivatives for colon cancer prevention and treatment.
- 14 August 2003
- Published by Springer Nature in Oncogene
- Vol. 22 (34) , 5298-5305
Tumor suppressor role for myopodin in bladder cancer: loss of nuclear expression of myopodin is cell-cycle dependent and predicts clinical outcome
Myopodin is a dual compartment protein that displays actin-bundling activity and redistributes between the nucleus and the cytoplasm in a differentiation-dependent and stress-induced fashion. We evaluated myopodin expression in initiation and progression of bladder cancer. Normal urothelium expresses myopodin in the cytoplasm and nuclei. Invasive bladder tumors showed decreased nuclear myopodin expression as compared to superficial lesions. This loss of nuclear myopodin expression was significantly associated with histopathological stage, tumor grade and overall patient survival in bladder tumors contained in tissue microarrays. We identified a differential nuclear expression for myopodin among bladder cancer cell lines during cell-cycle. Myopodin was present in the nucleus during G1/S in cells derived from superficial and low-grade lesions but not in those derived from invasive tumors. Loss of nuclear myopodin expression could classify bladder tumors and bladder cancer cell lines based on their histopathology. Most importantly, patients with preserved nuclear myopodin expression showed a longer survival. Nuclear myopodin expression in the context of cell-cycle progression may prove useful for staging bladder tumors and suggest a tumor suppressor role of myopodin in bladder cancer.
- 14 August 2003
- Published by Springer Nature in Oncogene
- Vol. 22 (34) , 5298-5305
Tumor suppressor role for myopodin in bladder cancer: loss of nuclear expression of myopodin is cell-cycle dependent and predicts clinical outcome
Myopodin is a dual compartment protein that displays actin-bundling activity and redistributes between the nucleus and the cytoplasm in a differentiation-dependent and stress-induced fashion. We evaluated myopodin expression in initiation and progression of bladder cancer. Normal urothelium expresses myopodin in the cytoplasm and nuclei. Invasive bladder tumors showed decreased nuclear myopodin expression as compared to superficial lesions. This loss of nuclear myopodin expression was significantly associated with histopathological stage, tumor grade and overall patient survival in bladder tumors contained in tissue microarrays. We identified a differential nuclear expression for myopodin among bladder cancer cell lines during cell-cycle. Myopodin was present in the nucleus during G1/S in cells derived from superficial and low-grade lesions but not in those derived from invasive tumors. Loss of nuclear myopodin expression could classify bladder tumors and bladder cancer cell lines based on their histopathology. Most importantly, patients with preserved nuclear myopodin expression showed a longer survival. Nuclear myopodin expression in the context of cell-cycle progression may prove useful for staging bladder tumors and suggest a tumor suppressor role of myopodin in bladder cancer.
- 1 August 2003
- Published by Elsevier in The American Journal of Pathology
- Vol. 163 (2) , 505-516
Gene Discovery in Bladder Cancer Progression using cDNA Microarrays
- 1 August 2003
- Published by Elsevier in The American Journal of Pathology
- Vol. 163 (2) , 505-516
Gene Discovery in Bladder Cancer Progression using cDNA Microarrays
- 1 February 2003
- Published by Elsevier in The American Journal of Pathology
- Vol. 162 (2) , 609-617
Tumor Suppressor Role of KiSS-1 in Bladder Cancer
- 1 February 2003
- Published by Elsevier in The American Journal of Pathology
- Vol. 162 (2) , 609-617
Tumor Suppressor Role of KiSS-1 in Bladder Cancer
- 1 January 2003
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 49 (1) , 23-31
Use of High-Throughput DNA Microarrays to Identify Biomarkers for Bladder Cancer
Background: Numerous markers have been described to correlate to some extent with tumor stage and prognosis of patients with bladder cancer. The power of many of these biomarkers in detecting superficial disease or predicting the clinical outcome of individual tumors is limited, and alternative markers are still in demand. High-throughput microarrays represent novel means for cancer research and tumor marker discovery. Approach: The aim of this report was to discuss the application of DNA technologies to provide novel biomarkers for bladder cancer. Content: Specific bladder tumor subtypes have distinct gene expression profiles. The use of high-throughput DNA microarrays allows identification of the most prevalent and relevant alterations within bladder tumors. Clusters of differentially expressed genes will become biomarkers to discriminate subgroups of patients with different histopathology or clinical outcome. Additionally, the identified individual molecular targets might be further validated and developed into novel serum or urinary biomarkers for the diagnosis and/or as prognostic factors to be applied in clinical practice. The diagnosis and prognosis of bladder cancer would be enhanced by the use of such markers, and the marker itself may constitute a therapeutic target when studied in appropriate patients and control groups. Summary: Expression profiling with high-throughput DNA microarrays has the potential of providing critical clues for the management of bladder cancer patients. As the quality, standardization, and ease of use of the technology increase and the costs decrease, DNA microarrays will move from being a technology restricted to research to clinical laboratories in the near future.
- 1 January 2003
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 49 (1) , 23-31
Use of High-Throughput DNA Microarrays to Identify Biomarkers for Bladder Cancer
Background: Numerous markers have been described to correlate to some extent with tumor stage and prognosis of patients with bladder cancer. The power of many of these biomarkers in detecting superficial disease or predicting the clinical outcome of individual tumors is limited, and alternative markers are still in demand. High-throughput microarrays represent novel means for cancer research and tumor marker discovery. Approach: The aim of this report was to discuss the application of DNA technologies to provide novel biomarkers for bladder cancer. Content: Specific bladder tumor subtypes have distinct gene expression profiles. The use of high-throughput DNA microarrays allows identification of the most prevalent and relevant alterations within bladder tumors. Clusters of differentially expressed genes will become biomarkers to discriminate subgroups of patients with different histopathology or clinical outcome. Additionally, the identified individual molecular targets might be further validated and developed into novel serum or urinary biomarkers for the diagnosis and/or as prognostic factors to be applied in clinical practice. The diagnosis and prognosis of bladder cancer would be enhanced by the use of such markers, and the marker itself may constitute a therapeutic target when studied in appropriate patients and control groups. Summary: Expression profiling with high-throughput DNA microarrays has the potential of providing critical clues for the management of bladder cancer patients. As the quality, standardization, and ease of use of the technology increase and the costs decrease, DNA microarrays will move from being a technology restricted to research to clinical laboratories in the near future.
- 1 December 2002
- Vol. 62 (23) , 6973-80
Molecular profiling of bladder cancer using cDNA microarrays: defining histogenesis and biological phenotypes.
This study was designed to characterize the expression profiles of nine bladder cancer cell lines (T24, J82, 5637, HT1376, RT4, SCaBER, TCCSUP, UMUC-3, and HT1197) using cDNA microarrays (8976 genes and expressed sequence tags). Novel targets involved in bladder cancer progression of potential clinical relevance were validated by immunohistochemistry using tissue microarrays of primary bladder tumors (n = 193 cases). Hierarchical clustering classified uroepithelial cells based on their histopathogenesis and cell cycle alterations. Keratin 10 and caveolin-1 transcripts were more abundant in tumor cells from squamous and invasive origin. Their combined expression was shown to stratify bladder tumors and define squamous differentiation. To assess the robustness of the clustering analysis, a bootstrap resampling technique was used. This grouped tumor cell lines based on their biological properties, including cell cycle and cell adhesion features. E-cadherin, zyxin, and moesin were identified as genes differentially expressed in these clusters and related to the p53, RB, and INK4A status of the cell lines. Loss of these adhesion molecules was associated with stage and grade in primary tumors (P < 0.05), and moesin expression was also associated with survival (P = 0.01). Deregulation of cell cycle and apoptotic pathways, such as mutations or altered expression of p53, pRB, and INK4A (p16), is necessary for uroepithelial transformation. However, it appears that deregulation of cell adhesion is a common event associated with tumor progression in uroepithelial neoplasms.
- 1 December 2002
- Vol. 62 (23) , 6973-80
Molecular profiling of bladder cancer using cDNA microarrays: defining histogenesis and biological phenotypes.
This study was designed to characterize the expression profiles of nine bladder cancer cell lines (T24, J82, 5637, HT1376, RT4, SCaBER, TCCSUP, UMUC-3, and HT1197) using cDNA microarrays (8976 genes and expressed sequence tags). Novel targets involved in bladder cancer progression of potential clinical relevance were validated by immunohistochemistry using tissue microarrays of primary bladder tumors (n = 193 cases). Hierarchical clustering classified uroepithelial cells based on their histopathogenesis and cell cycle alterations. Keratin 10 and caveolin-1 transcripts were more abundant in tumor cells from squamous and invasive origin. Their combined expression was shown to stratify bladder tumors and define squamous differentiation. To assess the robustness of the clustering analysis, a bootstrap resampling technique was used. This grouped tumor cell lines based on their biological properties, including cell cycle and cell adhesion features. E-cadherin, zyxin, and moesin were identified as genes differentially expressed in these clusters and related to the p53, RB, and INK4A status of the cell lines. Loss of these adhesion molecules was associated with stage and grade in primary tumors (P < 0.05), and moesin expression was also associated with survival (P = 0.01). Deregulation of cell cycle and apoptotic pathways, such as mutations or altered expression of p53, pRB, and INK4A (p16), is necessary for uroepithelial transformation. However, it appears that deregulation of cell adhesion is a common event associated with tumor progression in uroepithelial neoplasms.